StreetInsider.com News Articles

Form 4 Natera, Inc. For: Aug 10 Filed by: Sheena Jonathan

Fri, 14 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26933333.html

Form 4 Natera, Inc. For: Aug 10 Filed by: Sheena Jonathan

Fri, 14 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26933333.html

Form SCHEDULE 13G/A Natera, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926640.html

Form SCHEDULE 13G/A Natera, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926640.html

Natera (NTRA) PT Raised to $363.50 at Piper Sandler

Wed, 12 Aug 2026 09:18:54 -0400

Piper Sandler analyst Dave Westenberg raised the price target on Natera (NASDAQ: NTRA) to $363.50 (from $249.00) while maintaining a Overweight rating.

Natera (NTRA) PT Raised to $350 at Stephens

Wed, 12 Aug 2026 09:09:53 -0400

Stephens analyst Mason Carrico raised the price target on Natera (NASDAQ: NTRA) to $350.00 (from $305.00) while maintaining a Overweight rating.

Natera (NTRA) PT Raised to $360 at Guggenheim

Wed, 12 Aug 2026 06:53:21 -0400

Guggenheim analyst Subbu Nambi raised the price target on Natera (NASDAQ: NTRA) to $360.00 (from $290.00) while maintaining a Buy rating.

Natera to supply MRD testing for Kupando skin cancer trial

Wed, 12 Aug 2026 06:01:05 -0400

Natera, Inc. (NASDAQ: NTRA) announced a collaboration with Kupando Therapeutics to support a Phase 1 clinical trial evaluating KUP-101, an investigational immunotherapy candidate, according to a press release from the company.

Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used to monitor treatment response by assessing serial circulating tumor DNA (ctDNA) dynamics. The trial will enroll patients with advanced tumors across multiple skin cancer types, with Latitude MRD testing conducted at multiple timepoints during treatment.

The trial is being conducted at oncology centers in Germany. Kupando's safety committee has approved continued patient enrollment following the

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Wed, 12 Aug 2026 06:00:00 -0400

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testing

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics.

Under the agreement, Natera’s Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando’s clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial circulating tumor DNA (ctDNA) dynamics as part of treatment response monitoring. Patients with

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Wed, 12 Aug 2026 06:00:00 -0400

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testing

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Wed, 12 Aug 2026 06:00:00 -0400

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testing

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Wed, 12 Aug 2026 06:00:00 -0400

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testing

Natera (NTRA) PT Raised to $355 at Morgan Stanley

Mon, 10 Aug 2026 08:37:02 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Natera (NASDAQ: NTRA) to $355.00 (from $310.00) while maintaining a Overweight rating.

Natera (NTRA) PT Raised to $340 at Barclays

Mon, 10 Aug 2026 04:22:25 -0400

Barclays analyst Luke Sergott raised the price target on Natera (NASDAQ: NTRA) to $340.00 (from $260.00) while maintaining a Overweight rating.

Form 4 Natera, Inc. For: Aug 07 Filed by: Sheena Jonathan

Fri, 07 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260807/26892577.html

Form 4 Natera, Inc. For: Aug 07 Filed by: Sheena Jonathan

Fri, 07 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260807/26892577.html

Form 4 Natera, Inc. For: Aug 07 Filed by: Rabinowitz Matthew

Fri, 07 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260807/26892578.html

Form 4 Natera, Inc. For: Aug 07 Filed by: Rabinowitz Matthew

Fri, 07 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260807/26892578.html

Form 144 Natera, Inc. Filed by: Rabinowitz Matthew

Fri, 07 Aug 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260807/26892360.html

Form 144 Natera, Inc. Filed by: Rabinowitz Matthew

Fri, 07 Aug 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260807/26892360.html

Form S-8 Natera, Inc.

Fri, 07 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26892081.html

Form S-8 Natera, Inc.

Fri, 07 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26892081.html

Form 144 Natera, Inc. Filed by: Sheena Jonathan

Fri, 07 Aug 2026 10:41:00 -0400

si-local-file:///var/storage/secattach/20260807/26889069.html

Form 144 Natera, Inc. Filed by: Sheena Jonathan

Fri, 07 Aug 2026 10:41:00 -0400

si-local-file:///var/storage/secattach/20260807/26889069.html

Natera (NTRA) PT Raised to $385 at Bernstein SocGen Group

Fri, 07 Aug 2026 09:11:54 -0400

Bernstein SocGen Group analyst Eve Burstein raised the price target on Natera (NASDAQ: NTRA) to $385.00 (from $310.00) while maintaining a Outperform rating.